Published • loading... • Updated
Savannah Chrisley Gets Federal Warning Over Her Weight Loss Medicine Website
The FDA flagged misleading claims about compounded GLP-1 drugs on Savannah Chrisley's wellness site, requiring corrections within 15 business days without imposing fines.
- Last month, the U.S. Food and Drug Administration sent a warning letter to Unlocked podcast host Savannah Chrisley after reviewing GoodGirlRX.com for wording on weight-loss medicines.
- Regulators flagged claims about GLP‑1 products including semaglutide and tirzepatide, objecting to language like `FDA-approved meds` and `clinically proven GLP-1 results`, reminding Chrisley that compounded drugs are not FDA‑approved.
- After the warning, Chrisley's site implemented changes including disclaimers that GLP-1 drugs are not FDA-approved and replaced `clinically proven` with `clinically studied results`, with no fines issued.
- The FDA warned Savannah Chrisley she was in violation of federal law and gave her 15 business days to fix the site, with failure potentially leading to legal action.
- GoodGirlRX responded that it welcomes FDA guidance, while Savannah Chrisley told TMZ `This was about website wording, not patient safety` in response to the warning letter, with medical context explaining why claims about GLP‑1 drugs matter.
Insights by Ground AI
23 Articles
23 Articles
Reposted by
Entertainment Magazine
Feds Warn Savannah Chrisley Over Alleged False, Misleading Weight Loss Statements
Savannah Chrisley's prescription weight loss website is under a federal microscope ... 'cause the FDA warned her about making false and misleading claims about GLP-1s. The feds fired off a warning letter, obtained by TMZ, to Savannah last month ...…
·Los Angeles, United States
Read Full ArticleCoverage Details
Total News Sources23
Leaning Left5Leaning Right4Center4Last UpdatedBias Distribution38% Left
Bias Distribution
- 38% of the sources lean Left
38% Left
L 38%
C 31%
R 31%
Factuality
To view factuality data please Upgrade to Premium


















